Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus chemotherapy in relapsed small-cell lung cancer
2015-001097-18Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, topotecan in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Sep 2015; status: completed.
02
Drugs
nivolumabtopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2015-001097-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001097-18.